Get the Stockscreener App
1.82
1.62%
-0.03
Incannex Healthcare Inc stock is traded at $1.82, with a volume of 6,102.
It is down -1.62% in the last 24 hours and down -19.47% over the past month.
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.
See More
Previous Close:
$1.85
Open:
$1.9
24h Volume:
6,102
Relative Volume:
0.23
Market Cap:
$32.82M
Revenue:
-
Net Income/Loss:
$-21.91M
P/E Ratio:
-9.9075
EPS:
-0.1837
Net Cash Flow:
-
1W Performance:
-12.92%
1M Performance:
-19.47%
6M Performance:
-34.53%
1Y Performance:
+69.30%
1-Day Range:
$1.80
$1.90
1-Week Range:
$1.80
$2.11
52-Week Range:
$0.9501
$12.68
Incannex Healthcare Inc Stock (IXHL) Company Profile
Name
Incannex Healthcare Inc
Sector
Phone
61 409 840 786
Address
401 DOCKLANDS DRIVE, DOCKLANDS, VICTORIA
Compare IXHL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IXHL
Incannex Healthcare Inc
|
1.82 | 32.82M | 0 | -21.91M | 0 | -0.1837 |
|
ZTS
Zoetis Inc
|
176.74 | 80.59B | 9.15B | 2.43B | 2.31B | 4.92 |
|
HLN
Haleon Plc Adr
|
9.72 | 44.17B | 14.26B | 1.55B | 0 | 0.3327 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.57 | 42.61B | 30.27B | 1.93B | 3.45B | 0.444 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.57 | 18.77B | 16.77B | -959.00M | 1.37B | -2.00 |
|
VTRS
Viatris Inc
|
13.22 | 15.73B | 15.05B | -883.30M | 1.89B | 1.53 |
Incannex Healthcare Inc Stock (IXHL) Latest News
Incannex Healthcare Inc. Reports Earnings Results for the First Quarter Ended September 30, 2024 - Marketscreener.com
Incannex Healthcare (NASDAQ:IXHL) Shares Up 5.5% – Still a Buy? - Defense World
Incannex Healthcare (NASDAQ:IXHL) Trading Up 5.5%What's Next? - MarketBeat
Incannex Healthcare Inc (IXHL) Quarterly 10-Q Report - Quartzy
Incannex Healthcare Inc. Reports Fiscal First Quarter 2025 Financial Results and Business Updates - GlobeNewswire
Incannex Secures $59M Financing, Reports Q1 Results Amid Clinical Trial Progress | IXHL Stock News - StockTitan
Incannex Healthcare names Lou Barbato as chief medical officer - MSN
Incannex appoints new chief medical officer - Investing.com India
Incannex appoints new chief medical officer By Investing.com - Investing.com South Africa
Incannex Announces Appointment of Dr. Lou Barbato as Chief Medical Officer - GlobeNewswire
Incannex Healthcare Appoints Dr. Barbato as CMO - TipRanks
Incannex Healthcare Leads The Charge On US Penny Stocks With 2 Other Notable Picks - Simply Wall St
Incannex Healthcare secures $3.3 million through debt financing By Investing.com - Investing.com Australia
Incannex Healthcare secures $3.3 million through debt financing - Investing.com
Incannex Healthcare secures A$6.9 million funding By Investing.com - Investing.com Australia
Incannex Healthcare secures A$6.9 million funding - Investing.com
Incannex Provides Business Updates and Progress on OSA Drug Candidate in Phase 2/3 Trials - Sleep Review
Stonegate Initiates Coverage on Incannex Healthcare Inc. (IXHL) - Invezz
R&D tax breaks buoy Incannex as losses narrow - Green Market Report
Incannex Healthcare Inc. (NASDAQ:IXHL) Sees Significant Growth in Short Interest - Defense World
Incannex Healthcare Inc. Reports Fiscal Full Year 2024 Financial Results and Business Updates - The Manila Times
Incannex Healthcare Inc. (NASDAQ:IXHL) Short Interest Update - MarketBeat
Incannex Secures Up to $60M in Financing to Support Clinical Trials - Sleep Review
Incannex secures financing deal valued at US$60 million - Mugglehead
Incannex $60 Million Deal With Arena For Late-Stage Drug TrialsIncannex Healthcare (NASDAQ:IXHL) - Benzinga
Incannex Healthcare secures $60 million funding via equity and debt - Investing.com
Incannex Healthcare secures $60 million funding via equity and debt By Investing.com - Investing.com UK
Incannex Healthcare lands $60 million financing deal - Green Market Report
Incannex Healthcare Announces Strategic Financing for up to $60 Million with Arena Investors - GlobeNewswire
Incannex secures $60 million in funding for clinical trials - Investing.com
Incannex Healthcare Inc. (NASDAQ:IXHL) Sees Large Growth in Short Interest - MarketBeat
Thinking about buying stock in Altimmune, UiPath, Incannex Healt - GuruFocus.com
Virtu Financial LLC Buys New Shares in Incannex Healthcare Inc. (NASDAQ:IXHL) - Defense World
4 Psychedelic Stocks to Consider as Clinical Trials Heat up - Investing.com
FDA Review of PsiGAD2 IND complete; clinical trial for - GlobeNewswire
FDA Clears Incannex To Proceed With Phase 2 Psilocybin-Assisted Therapy Trial For Anxiety - Benzinga
Incannex Healthcare gets FDA nod for Phase 2 trial - Green Market Report
FDA Review of PsiGAD2 IND complete; clinical trial for Psilocybin Assisted Psychotherapy in Patients with Generalised Anxiety Disorder to Proceed - StockTitan
Tidal Investments LLC Buys New Stake in Incannex Healthcare Inc. (NASDAQ:IXHL) - MarketBeat
Tidal Investments LLC Acquires Shares of 423,410 Incannex Healthcare Inc. (NASDAQ:IXHL) - Defense World
Dosing completed in 115 participant bioavailability/bioequivalence clinical trial for proprietary sleep apnea drug candidate IHL-42X - GlobeNewswire
Incannex Healthcare Inc Stock (IXHL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.83%
1.03%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):